Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shanghai) confirms that Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has obtained necessary approvals for the repurchase and cancellation of part of its restricted stock under the 2024 incentive plan, which is in compliance with relevant laws and regulations [1][9]. Group 1: Approval and Authorization of Repurchase - On May 16, 2024, the company's board of directors approved the draft of the 2024 restricted stock incentive plan and related proposals [5]. - On June 3, 2024, the company held a temporary shareholders' meeting to approve the incentive plan and related proposals [6]. - The board and supervisory committee verified the list of recipients for the restricted stock grants and the repurchase of stocks on subsequent meetings [6][9]. Group 2: Details of the Repurchase - The repurchase is based on the provision that if an incentive recipient leaves the company, the unvested restricted stocks will be repurchased at the grant price of 4.73 yuan per share, plus interest [7]. - A total of 60,000 shares will be repurchased due to one recipient's departure [7]. - The funds for the repurchase will come from the company's own funds [9]. Group 3: Conclusion and Compliance - The legal opinion concludes that the repurchase of restricted stocks has met the necessary approvals and is compliant with the relevant regulations and the incentive plan [9]. - The company must still complete the cancellation registration and related procedures as per the Company Law and fulfill information disclosure obligations [9].

Core Viewpoint - The legal opinion issued by Grandway Law Offices confirms that Guangdong Yinhui Technology Co., Ltd. has met the conditions for the first unlock period of its 2024 restricted stock incentive plan, allowing 47 individuals to unlock a total of 5.56 million shares [1][9]. Group 1: Unlock Conditions - A total of 47 individuals are eligible for the unlock, with 5.56 million shares available for release, which represents a significant portion of the company's total share capital [2][9]. - The first unlock period allows for 50% of the restricted shares to be released after 12 months from the grant date, with a second unlock period allowing for the remaining 50% after 24 months [2][3]. - The conditions for unlocking include meeting specific performance targets, such as achieving a net profit of no less than 40 million yuan in 2024 and 48 million yuan in 2025 [4][5]. Group 2: Compliance and Procedures - The company has followed necessary procedures, including board approval and verification of the eligibility of the 47 individuals, ensuring compliance with relevant regulations [7][8]. - The independent directors have confirmed that the conditions for unlocking have been met and that the company has the necessary qualifications to implement the stock incentive plan [8][9]. - The legal opinion concludes that all required legal procedures have been fulfilled, and the conditions for unlocking the restricted shares have been satisfied, pending the formal unlocking process [9].

Core Viewpoint - The report outlines the conditions for the first unlock period of the 2024 stock incentive plan for Guangdong Yinxin Technology Co., Ltd, confirming that the necessary conditions for unlocking have been met [1][10][14] Group 1: Independent Financial Advisor Report - The independent financial advisor, Shanghai Miaodao Enterprise Management Consulting Co., Ltd, was commissioned to provide an opinion on the 2024 stock incentive plan for Yinxin Technology [1][2] - The report is based on the assumption that there are no significant changes in laws, regulations, or the market environment affecting the company [5][6] - The advisor confirms that the information provided by Yinxin Technology is accurate and complete, and there are no substantial discrepancies in the disclosed documents [2][3] Group 2: Conditions for Unlocking - The first unlock period for the stock incentive plan began on July 17, 2024, and ended on July 16, 2025, allowing for the unlocking of 50% of the granted restricted stocks [10][11] - The company has not encountered any negative audit opinions or violations of profit distribution regulations, thus meeting the conditions for unlocking [10][12] - The performance target for the company in 2024 was set at a net profit of no less than 40 million yuan, which was achieved, allowing for the unlocking of stocks [12][13] Group 3: Details of the Unlocking - A total of 47 individuals met the conditions for unlocking, with 5.56 million shares eligible for release, representing 1.16% of the company's total shares [13][14] - The unlocking process involved adjustments due to one individual voluntarily giving up their shares, reducing the total from 49 to 48 participants [10][13] - The company plans to repurchase and cancel any shares that do not meet the unlocking conditions due to individual performance evaluations [12][13]

Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is implementing a 2025 restricted stock incentive plan, which has received necessary approvals and is in compliance with relevant laws and regulations [1][3][6]. Group 1: Legal Framework and Compliance - The law firm Grandall (Shanghai) has been appointed as the legal advisor for the company's 2025 restricted stock incentive plan, ensuring compliance with the Company Law, Securities Law, and other relevant regulations [1][2]. - The law firm has confirmed that the legal opinion provided is based on existing facts and applicable laws, and it will bear legal responsibility for the opinion issued [2][3]. Group 2: Approval Process - The approval process for the incentive plan included multiple meetings: the board meeting on July 21, 2025, where the draft plan was approved, and the shareholders' meeting on August 7, 2025, which also approved the plan [3][4]. - The board of directors held a subsequent meeting on August 8, 2025, to approve the first grant of restricted stocks to the incentive targets [4][6]. Group 3: Grant Details - The first grant of restricted stocks is set for August 8, 2025, with a total of 7.95 million shares to be granted to 171 eligible incentive targets at a price of 5.60 yuan per share [6][7]. - The granting conditions include compliance with specific financial and regulatory criteria, ensuring that the company meets the necessary standards for stock incentives [5][6]. Group 4: Conclusion - The law firm concludes that the incentive plan's first grant has obtained the required authorizations and approvals, and all conditions for granting the restricted stocks have been met [6][7].

Core Points - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced the repurchase and cancellation of 60,000 restricted stocks from the 2024 incentive plan due to one incentive object leaving the company [1][4][8] - The repurchase price is set at 4.73 yuan per share, with interest equivalent to the bank's term deposit rate [1][6] - The total amount for the repurchase is 283,800 yuan, sourced from the company's own funds [6][8] Decision Process and Disclosure - The decision to repurchase was approved during the 31st meeting of the fifth board of directors on August 8, 2025, following the necessary procedures and disclosures [1][4] - The supervisory board confirmed that no objections were raised during the public notice period regarding the incentive plan [2][4] Stock Structure Changes - Before the repurchase, the total number of restricted shares was 21,014,468, which will decrease to 20,954,468 after the cancellation [7] - The total share capital will change from 248,318,563 to 248,258,563 shares [7] Impact on the Company - The repurchase and cancellation of the restricted stocks will not significantly affect the company's financial status, operational results, or the ongoing implementation of the incentive plan [4][8] - The management team is committed to fulfilling their responsibilities and creating value for shareholders [4][8] Committee and Legal Opinions - The Compensation and Assessment Committee approved the repurchase, confirming compliance with relevant regulations and the accuracy of the number and price of the stocks [8] - Legal opinions from Guohao Law Firm indicate that the company has obtained necessary approvals and must submit the matter for shareholder approval [8]

证券代码：300221 证券简称：银禧科技 公告编号：2025-48 广东银禧科技股份有限公司 关于 2024 年限制性股票激励计划首次授予第一类限制性股票第 告本激励计划草案时在公司（含子公司）任职并与公司或子公司签署劳动合同或 聘用合同的董事、高级管理人员及核心骨干人员。 约占本激励计划草案公布日公司股本总额 47,455.7935 万股的 2.73%。其中，首 次授予限制性股票 1,124.00 万股，约占本激励计划草案公布日公司股本总额的 本激励计划草案公布日公司股本总额的 0.36%，占本激励计划拟授出限制性股票 总数的 13.27%。 象获授的限制性股票完成登记之日起算。授予日与首次解除限售日之间的间隔不 得少于 12 个月。 一个解除限售期解除限售条件成就的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 售暨上市流通的公告，敬请投资者关注。 广东银禧科技股份有限公司（以下简称"银禧科技"或"公司"）于 2025 年 8 月 《关于 2024 年限制性股票激励计划首次授予第一类限制性股票第一个解除限售 期解除限售条件成就的议案》， ...

证券代码：301558 证券简称：三态股份 公告编号：2025-027 深圳市三态电子商务股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划首次 授予激励对象名单的核查意见及公示情况说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市三态电子商务股份有限公司（以下简称"公司"）于 2025 年 7 月 28 日召开第六届董事会第四次会议和第六届监事会第四次会议，审议通过了《关于 <深圳市三态电子商务股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草案 ="草案"> 及其 摘要的议案》等相关议案，具体内容详见公司于 2025 年 7 月 29 日在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以 下简称"《上市规则》"）、《深圳证券交易所创业板上市公司自律监管指南第 规 ...

深圳市三态电子商务股份有限公司 监事会关于 2025 年限制性股票激励计划首次授予激励对象名单 的核查意见及公示情况说明 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市三态电子商务股份有限公司（以下简称"公司"）于 2025 年 7 月 28 日召开第六届董事会第四次会议和第六届监事会第四次会议，审议通过了《关于 <深圳市三态电子商务股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草案 ="草案"> 及其 证券代码：301558 证券简称：三态股份 公告编号：2025-028 事会反馈意见； 予激励对象提出异议的反馈。 （二）监事会对拟首次授予激励对象的核查方式 公司监事会核查了本次激励计划拟首次授予激励对象的名单、身份证件、与 公司（含分公司及子公司，下同）签订的劳动合同或聘用合同、在公司担任的职 务等相关信息。 二、监事会核查意见 根据《管理办法》《上市规则》《自律监管指南第 1 号》《公司章程》的规 定和公司对拟首次授予激励对象名单的公示情况，并结合监事会的核查结果，监 事会发表核查意见如下： 摘要的议案》等 ...

Group 1 - The company held its 15th meeting of the 7th Board of Directors on August 8, 2025, with all 8 directors present, ensuring compliance with relevant laws and regulations [1] - The Board approved a proposal to change the registered capital and amend the Articles of Association, with a unanimous vote of 8 in favor [1] - The Board also approved the first unlock conditions of the 2024 restricted stock incentive plan, confirming that the conditions for unlocking have been met [2] Group 2 - A new department, "Strategic Business Development Center," was proposed to enhance the company's strategic foresight and new business incubation capabilities, focusing on various strategic responsibilities [2]

Core Points - The company held its 16th meeting of the 11th Board of Directors on August 7, 2025, where several key resolutions were passed, including the approval of the first lock-up period for the 2022 restricted stock incentive plan [1][12][13] - A total of 65 individuals met the conditions for the release of 377,600 shares from the first lock-up period, which represents 0.044% of the company's total share capital of 857,213,183 shares [15][26][32] - The company will hold its second extraordinary general meeting of shareholders on August 28, 2025, to approve the resolutions passed by the Board [9][46] Summary by Sections Board Resolutions - The Board approved the release of the first lock-up period for the 2022 restricted stock incentive plan, with 11 votes in favor and none against [1][12] - The Board also approved the election of a new director, Chiuhang Zheng, to replace Liu Xunzhang, who will no longer serve as a director or audit committee member [3][39] - The appointment of Yu Liwei as the new securities affairs representative was approved, replacing Liu Jianning [6][43] Monitoring and Legal Opinions - The Supervisory Board confirmed that the conditions for the release of the first lock-up period for the restricted stock incentive plan had been met, with 65 individuals eligible for the release [13][33] - Legal opinions were provided by Shandong Songmao Law Firm and independent financial advisor Shanghai Rongzheng Enterprise Consulting Service Group, confirming compliance with relevant regulations [2][34][35] Shareholder Meeting - The company announced the date and details for the second extraordinary general meeting of shareholders, scheduled for August 28, 2025, with a record date of August 22, 2025 [9][46][51]